Abstract
A single center randomized double dummy study was undertaken in 116 patients; 59 were randomized to mesalamine and 57 to receive a nonpathogenic strain of Escherichia coli. In addition, all patients received standard medical therapy, together with a 1-wk course of oral gentamicin. After remission, patients were maintained on either mesalamine or E. coli and observed for a maximum of 12 months. Duration of remission was slightly higher in the mesalamine group relative to the E. coli group (206 vs 185 days). Similarly, the percentage of patients undergoing remission was equivalent (73% vs 67%), again slightly favoring the mesalamine group. The authors, therefore, conclude that a nonpathogenic strain of E. coli has an effectiveness almost equivalent to that of mesalamine in maintaining remission of ulcerative colitis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
